Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers.

Next Previous
Trial Profile

A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics

Most Recent Events

  • 04 Mar 2016 Biomarkers information updated
  • 19 Jan 2012 Primary endpoints and additional lead trial investigator identified as reported by ClinicalTrials.gov.
  • 19 Jan 2012 New source identified and integrated (NCT01513135; ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top